GleamWall
中文EN

NRXS Neuraxis, INC

Electromedical & Electrotherapeutic Apparatus · NYSE · SEC CIK 1933567 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY94.3%
TTM net income YoY-60.5%
TTM EPS YoY-9.1%
Revenue 3-yr CAGR37.0%
Net income 3-yr CAGR—

Margins

Gross margin86.2%
Operating margin-186.2%
Net margin-185.2%
FCF margin—
EBITDA margin-185.0%

Returns

ROE-409.7%
ROA-194.7%
ROIC (approx.)—
Asset turnover1.05x

Leverage & solvency

Liabilities / assets45.6%
Debt / equity0.00x
Current ratio2.10x
Interest coverage-128.36x

Cash quality & payout

Operating cash flow / net income0.53x
Accruals ratio-90.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$2.03M$1.93M$1.61M$968,127$811,414$894,086$895,655$761,165
Cost of revenue$271,663$272,573$218,366$141,651$135,487$146,643$139,475$105,053
Gross profit$1.76M$1.66M$1.39M$826,476$675,927$747,443$756,180$656,112
R&D expense$288,745$274,344$99,567$146,178$130,850$115,197$117,867$138,426
SG&A expense$7.05M$2.65M$2.21M$1.81M$1.88M$1.82M$2.43M$1.53M
Operating income-$6.58M-$2.12M-$1.74M-$1.72M-$2.10M-$1.72M-$2.30M-$1.47M
Interest expense$20,126$19,794$26,189$28,636$29,661$13,434$2,237$2,394
Net income-$6.55M-$2.09M-$1.76M-$1.71M-$2.12M-$1.69M-$2.28M-$1.45M
EBITDA-$6.56M-$2.11M-$1.72M-$1.69M-$2.08M-$1.70M-$2.29M-$1.46M
EPS (basic)-0.52-0.19-0.18—-0.24-0.22-0.33—
EPS (diluted)-0.52-0.19-0.18—-0.24-0.22-0.33—
Weighted avg. shares (diluted)12.99M12.12M10.95M—9.88M8.52M7.46M—
Banking
Deposits—$31,174$29,585$28,660$37,160$31,927$37,684$32,527
Balance sheet
Cash & equivalents$4.48M$8.32M$7.08M$4.97M$4.38M$5.99M$2.01M$3.70M
Receivables$809,341$432,925$385,009$195,703$108,504$128,518$243,708$244,618
Inventory$254,656$277,308$238,282$257,132$110,256$131,432$37,421$44,328
Current assets$6.05M$9.41M$8.14M$5.73M$4.99M$6.62M$2.54M$4.27M
PP&E, net$56,921$65,463$67,530$75,564$85,473$101,104$103,715$89,982
Intangibles$263,734$258,214$266,494$274,778$283,062$91,345$93,967$96,588
Total assets$6.66M$10.00M$8.75M$6.40M$5.78M$7.09M$3.03M$4.76M
Current liabilities$2.89M$3.10M$2.81M$2.79M$3.15M$2.35M$2.10M$2.43M
Short-term debt$207,306$42,726$100,735$148,293$195,658$121,433$84,307$154,152
Total liabilities$3.03M$3.26M$3.00M$3.00M$3.49M$2.83M$2.77M$2.69M
Shareholders' equity$3.62M$6.74M$5.75M$3.40M$2.28M$4.25M$258,479$2.07M
Shares outstanding13.81M12.47M11.45M10.65M9.89M9.86M7.22M6.99M
Cash flow statement
Operating cash flow-$2.27M-$1.03M-$1.23M-$1.93M-$1.43M-$1.47M-$1.60M-$1.76M
Capital expenditure$0——$5,862$0$7,288$18,000$0
Free cash flow-$2.27M——-$1.94M-$1.43M-$1.47M-$1.62M-$1.76M
Investing cash flow-$13,800——-$105,862$0-$7,288-$18,000$0
Financing cash flow-$1.56M$2.28M$3.34M$2.63M-$183,808$5.46M-$69,845$5.19M
Depreciation & amortization$16,821$16,650$16,317$24,055$16,205$12,885$6,356$6,851
Stock-based compensation$4.06M$0$329,434$157,136$0$0$105,811$0

Free plan shows the latest 8 periods; Pro shows all 19 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.